Analysis of the clinical efficacy and safety of early application of tirofiban combined with urokinase intravenous thrombolysis in the treatment of acute ischemic stroke
Objective To investigate the clinical efficacy and safety of early application of tirofiban combined with urokinase intravenous thrombolysis in the treatment of acute ischemic stroke(AIS).Methods Ninety-six patients with AIS treated in our hospital from June 2019 to September 2022 were selected as research objects.According to different treatment plans,they were divided into an observation group and a control group.The observation group was treated with tirofiban combined with urokinase intravenous thrombolysis.The control group was treated with single urokinase intravenous thrombolysis.The clinical efficacy,platelet-related parameters such as platelet mean distribution width(PDW),platelet density(PCT),platelet adhesion rate(PAdT)and platelet ag-gregation rate(PAgT)were compared between the two groups.The neurological function was evaluated using the National Institutes of Health Stroke Scale(NIHSS)and the Barthel index(Barthel index of ADL)was used to evaluate activities of daily living.The safety was also analyzed.Results The total clinical curative effect in the observation group was 96.30%that was higher than 76.19%in the control group(P<0.05).After treatment,the levels of PDW,PAdT,and PAgT were decreased and the level of PCT was increased in both groups compared with those before treatment,and the changes in the observation group were greater than those in the control group(P<0.05).After treatment,the NIHSS scores were decreased and the Barthel index was increased in both groups compared with that before treatment,and the NIHSS score was lower and the Barthel index was higher in the observation group than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusions The application of tirofiban combined with urokinase intravenous thrombolysis is effective in the early treatment of AIS patients.It can improve the neurological function and daily living ability of the patients.The treatment is safe and reliable,and is worthy of clinical promotion.
TirofibanIntravenous thrombolysis with urokinaseAcute ischemic strokeClinical efficacySafety
NETL
NSTL
万方数据
